Edition:
United Kingdom

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

452.25INR
23 May 2018
Change (% chg)

Rs-0.75 (-0.17%)
Prev Close
Rs453.00
Open
Rs454.00
Day's High
Rs461.50
Day's Low
Rs449.45
Volume
4,549,341
Avg. Vol
5,687,159
52-wk High
Rs630.85
52-wk Low
Rs432.70

Chart for

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.05
Market Cap(Mil.): Rs1,272,113.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.66

Financials

  SUN.NS Industry Sector
P/E (TTM): 28.37 30.95 32.75
EPS (TTM): 18.69 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

UPDATE 2-India's Sun Pharma warns U.S. pricing pressure to hit 2019 profit

* Plans to reduce "unviable" generics research (Adds managing director comments from conference call)

25 May 2018

India's Sun Pharma Industries Q4 profit up 7 pct, beats estimates

May 25 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, posted fourth-quarter net profit way above expectations.

25 May 2018

BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

* UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA

18 Apr 2018

BRIEF-Sun Pharmaceutical Industries Gets U.S. FDA Nod Of ILUMYA (Tildrakizumab-Asmn)

* CO GETS U.S. FDA APPROVAL OF ILUMYA (TILDRAKIZUMAB-ASMN) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text - http://bit.ly/2HRX8j1 Further company coverage:

21 Mar 2018

BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility

* SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018

23 Feb 2018

UPDATE 1-India's Sun Pharma quarterly profit plunges on weak U.S. sales

* Profit hit by one-time deferred tax adjustment (Adds details)

14 Feb 2018

BRIEF-Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct

* SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR Source text for Eikon: Further company coverage:

14 Feb 2018

India's Sun Pharma Q3 profit slides 75 pct, misses estimates

Feb 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd reported on Wednesday a 75 percent drop in net profit in the quarter ending Dec. 31, well below analysts' estimates.

14 Feb 2018

BRIEF-India's Sun Pharmaceutical Industries Dec-Qtr Consol Profit Down 75 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.65 BILLION RUPEES VERSUS PROFIT OF 14.72 BILLION RUPEES LAST YEAR

14 Feb 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

16 Jan 2018

Earnings vs. Estimates